Abstract
In the nonamyloidogenic processing pathway the Alzheimers amyloid precursor protein (APP) is proteolytically cleaved by α-secretase. As this cleavage occurs at the Lys16-Leu17 bond within the amyloid β domain, it prevents deposition of intact amyloidogenic peptide. In addition, the large ectodomain (sAPPα) released by the action of α-secretase has several neuroprotective properties. Studies with a range of hydroxamic acid-based compounds, such as batimastat, indicate that α-secretase is a zinc metalloproteinase, and members of the adamalysin family of proteins, TACE, ADAM10 and ADAM9, all fulfil some of the criteria required of α-secretase. APP is constitutively cleaved by α-secretase in most cell lines. However, on stimulation with muscarinic agonists or activators of protein kinase C, such as phorbol esters, the α-secretase cleavage of APP is up-regulated. The constitutive α- secretase activity is primarily at the cell surface, while the regulated activity is predominantly located within the Golgi. The beneficial action of cholinesterase inhibitors may in part be due to activation of muscarinic receptors, resulting in an up-regulation of α-secretase. Other agents can also increase the nonamyloidogenic cleavage of APP including estrogen, testosterone, various neurotransmitters and growth factors. As the α- secretase cleavage of APP both precludes the deposition of the amyloid β peptide and releases the neuroprotective sAPPα, pharmacological up-regulation of α-secretase may provide alternative therapeutic approaches for Alzheimers disease.
Keywords: alpha secretase, lys16-leu17, sappalpha
Current Medicinal Chemistry
Title: The Search for α-Secretase and its Potential as a Therapeutic Approach to Alzheimers Disease
Volume: 9 Issue: 11
Author(s): N. M. Hooper and A. J. Turner
Affiliation:
Keywords: alpha secretase, lys16-leu17, sappalpha
Abstract: In the nonamyloidogenic processing pathway the Alzheimers amyloid precursor protein (APP) is proteolytically cleaved by α-secretase. As this cleavage occurs at the Lys16-Leu17 bond within the amyloid β domain, it prevents deposition of intact amyloidogenic peptide. In addition, the large ectodomain (sAPPα) released by the action of α-secretase has several neuroprotective properties. Studies with a range of hydroxamic acid-based compounds, such as batimastat, indicate that α-secretase is a zinc metalloproteinase, and members of the adamalysin family of proteins, TACE, ADAM10 and ADAM9, all fulfil some of the criteria required of α-secretase. APP is constitutively cleaved by α-secretase in most cell lines. However, on stimulation with muscarinic agonists or activators of protein kinase C, such as phorbol esters, the α-secretase cleavage of APP is up-regulated. The constitutive α- secretase activity is primarily at the cell surface, while the regulated activity is predominantly located within the Golgi. The beneficial action of cholinesterase inhibitors may in part be due to activation of muscarinic receptors, resulting in an up-regulation of α-secretase. Other agents can also increase the nonamyloidogenic cleavage of APP including estrogen, testosterone, various neurotransmitters and growth factors. As the α- secretase cleavage of APP both precludes the deposition of the amyloid β peptide and releases the neuroprotective sAPPα, pharmacological up-regulation of α-secretase may provide alternative therapeutic approaches for Alzheimers disease.
Export Options
About this article
Cite this article as:
Hooper M. N. and Turner J. A., The Search for α-Secretase and its Potential as a Therapeutic Approach to Alzheimers Disease, Current Medicinal Chemistry 2002; 9 (11) . https://dx.doi.org/10.2174/0929867023370121
DOI https://dx.doi.org/10.2174/0929867023370121 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
3,4-Dihydropyrimidin-2(1H)-one C5 Amides as Inhibitors of T NFα Production: Synthesis, Biological Evaluation and Molecular Modeling
Letters in Drug Design & Discovery Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Intervention of Proliferation and Differentiation of Endogenous Neural Stem Cells in the Neurodegenerative Process of Huntingtons Disease Phenotype
CNS & Neurological Disorders - Drug Targets Severe Asthma: Why do Some Children Not Respond to Treatment?
Current Pediatric Reviews DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies
CNS & Neurological Disorders - Drug Targets Drugs Treatment of Pain in Multiple Sclerosis
Current Clinical Pharmacology The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Small Molecule Antagonists of the Tachykinin NK2 Receptor [General Reviews]
Mini-Reviews in Medicinal Chemistry From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Current Topics in Medicinal Chemistry Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Acetylcholinesterase Inhibition in Alzheimers Disease
Current Pharmaceutical Design Statistical Voxel-Based Methods and [18F]FDG PET Brain Imaging: Frontiers for the Diagnosis of AD
Current Alzheimer Research Differential Effects of Doxazosin on Renin-Angiotensin-System- Regulating Aminopeptidase Activities in Neuroblastoma and Glioma Tumoral Cells
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Neuropharmacology Inhibitors of Monoamine Oxidase and Acetylcholinesterase as a Front Runner in CNS Drug Discovery
Combinatorial Chemistry & High Throughput Screening Alpha-1-Antichymotrypsin: A Common Player for Type 2 Diabetes and Alzheimer's Disease
Current Diabetes Reviews Comparative Effectiveness of Agmatine and Choline Treatment in Rats with Cognitive Impairment Induced by AlCl<sub>3</sub> and Forced Swim Stress
Current Clinical Pharmacology Video Game Addiction: Past, Present and Future
Current Psychiatry Reviews The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice
Current Neuropharmacology Interleukin-1 Drives Cerebrovascular Inflammation via MAP Kinase-Independent Pathways
Current Neurovascular Research